WSTF (Williams syndrome transcription factor) inhibitors, specifically targeting the BAZ1B protein, are a class of chemical compounds designed to modulate the function of the BAZ1B gene product. BAZ1B, also known as WSTF, is a component of the WICH (WSTF-ISWI chromatin remodeling) complex, which plays a crucial role in chromatin dynamics, gene expression regulation, and DNA repair. This complex is particularly involved in processes like nucleosome sliding and chromatin remodeling, which are essential for maintaining genomic stability and proper transcriptional regulation. WSTF-BAZ1B interacts with various chromatin-associated proteins and modifies chromatin structure through the deposition of histone variants, specifically H2A.X during DNA damage response, which is crucial for recruiting other factors that repair DNA breaks.
Inhibitors targeting BAZ1B are of particular interest in studies focused on epigenetics and chromatin biology due to the pivotal role WSTF plays in organizing chromatin structure and facilitating DNA accessibility. These inhibitors work by disrupting the WICH complex, potentially altering chromatin states and reducing or enhancing the accessibility of specific genomic regions to transcription factors and repair machinery. BAZ1B inhibitors are often studied in the context of gene expression modulation, where they can be used to elucidate the broader roles of chromatin remodeling complexes in cellular processes such as differentiation, proliferation, and genomic integrity. Researchers employ these inhibitors to investigate the fine-tuning of chromatin dynamics, offering insight into the mechanistic underpinnings of transcriptional regulation and the complex orchestration of DNA repair mechanisms at a molecular level.
SEE ALSO...
| Product Name | CAS # | Catalog # | QUANTITY | Price | Citations | RATING |
|---|---|---|---|---|---|---|
(±)-JQ1 | 1268524-69-1 | sc-472932 sc-472932A | 5 mg 25 mg | $231.00 $863.00 | 1 | |
A thieno-triazolo-1,4-diazepine that targets the bromodomains of the BET family members, including BRD2, BRD3, BRD4, and BRDT. | ||||||
GSK 525762A | 1260907-17-2 | sc-490339 sc-490339A sc-490339B sc-490339C sc-490339D | 5 mg 10 mg 50 mg 100 mg 1 g | $300.00 $540.00 $940.00 $1680.00 $5900.00 | ||
A quinazoline derivative that also targets BET bromodomains. | ||||||
(S)-2-(4-(4-Chlorophenyl)-2,3,9-trimethyl-6H-thieno[3,2-f][1,2,4]triazolo[4,3-a][1,4]diazepin-6-yl)-N-(4-hydroxyphenyl)acetamide | 202590-98-5 | sc-501130 | 2.5 mg | $330.00 | ||
An inhibitor with a structure similar to JQ1, targeting BET bromodomains. | ||||||
RVX 208 | 1044870-39-4 | sc-472700 | 10 mg | $340.00 | ||
Primarily developed for cardiovascular diseases, it targets BET bromodomains with a slightly different mechanism. | ||||||
CPI-0610 | 1380087-89-7 | sc-507490 | 10 mg | $495.00 | ||
A potent BET inhibitor. | ||||||
PFI 3 | 1819363-80-8 | sc-507340 | 10 mg | $300.00 | ||
A selective inhibitor for the bromodomains of SMARCA2 and SMARCA4, members of the SWI/SNF chromatin remodeling complex. | ||||||